New heart attack drug, launched
AstraZeneca Philippines has launched ticagrelor, an innovative medicine that can help save the lives of patients with acute coronary syndrome (ACS), an umbrella term for conditions ranging from unstable angina—unremitting chest pain that threatens a heart attack—to actual heart attack, resulting from insufficient blood supply to the heart muscle.
“AstraZeneca’s commitment to research and development in cardiovascular medicine enabled us to identify unmet needs and potential areas for improvement in oral anti-platelet therapy that led to the development of ticagrelor,” said Milagros Tan, M.D., medical director of AstraZeneca Philippines, during the ticagrelor launch last August 1 at the Crowne Plaza Galleria Hotel in Quezon City.
Ticagrelor belongs to a new class of oral antiplatelet treatment for ACS that works by preventing the formation of new blood clots and maintaining blood flow in the body to help reduce a patient’s risk of suffering another (potentially fatal) heart attack.
From left: Fed Cheng, M.D., consultant cardiologist at the Cardinal Santos Medical Center; Eugene Reyes, M.D., vice president of the Philippine Heart Association (PHA); Milagros Tan, M.D.; John French, M.D., director of CCU and Cardiovascular Research at Liverpool Hospital in Sydney, Australia; and Mr. Gagan Singh, country president of AstraZeneca Philippines.